Fig. 4From: Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Top 3 ‘most impactful new therapies for BCG-unresponsive NMIBC patients’, as ranked by physicians (n = 508)Back to article page